Sangamo Biosciences Inc (SGMO)

[Fress]

SGMO has major potential just signed huge deal with Biogen giving them cash into 2023 Deep pipeline top Gene Editing company in the world will be worth more than Crisper soon

One needs to think of the patient population. The R&D presentation had 5M Alzheimer's patients and Parkinson's was 1M. A genome regulation would be likely priced as gene therapy, at $1M. The market potential is about $6 Trillion. At 9% royalty, think $540B to Sangamo. agreement means to Sangamo. BTW Biogen shares are in an escrow, cannot be sold for one year, and then they may be sold in 50% drops until 5% is reached.

Biogen is also forbidden to buy shares on the open market, just in case they want to take over, or worse sell short own holding.

Pfizer is adding two patients to phase 2 to copy BioMarin 7 patients and have a mirror image. Judging by the moves of BioMarin, Pfizer could be filing BLA by February 2021. Between now and then, data drops to keep BioMarin at bay would be likely. At $10, including Biogen investment, the stock is worth $1.4B. Biogen did not select CRSP for it, as the method cannot make precise regulation. Vertex sold half shares of CRSP, but WS barrel fish bought up CRSP to over $4.2B. That's $33 for Sangamo share. None of the CRSP deals are like the ones for Sangamo, and Vertex seems to be moving out, not because it needs money.
Keep your shares, people,

17% shares in Biogen's hands. That is the point. Shorts are not getting those shares. Equity investment is much more attractive than selling to the markets, and shorts to cover. Sangamo is getting $350M, and secures cash runway for another two years, in worse case 2023.

https://www.sangamo.com/pipeline

$SGMO